Zhengye Biotechnology Holding Limited
NASDAQ:ZYBTDrug Manufacturers - Specialty & Generic
+$7.31 today
- Market cap
- $71.09M
- Beta
- -2.17
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$1.50
Volume 0.02M
Average 0.10M
ZYBT Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT
Deferred Revenue · Q4 FY2025 · quarter ended Dec 2025
Deferred revenue rises 31.0% from a year ago
Deferred revenue stood at CN¥4.83M at the end of Q4 FY2025, up 31.0% from a year earlier. Over 3 fiscal years it compounded at +0.9% a year.
Context
- Deferred revenue amounted to 1.1% of total assets at the end of Q4 FY2025, up 0.4 pp from a year earlier.
- Deferred revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps rising in the next quarterly balance sheet after a +31.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
CNY · from the balance sheet
- Latest · FY2025
- 4.83M CNY
- Year-over-year change
- +31.0%
- 4-year CAGR
- +3.0%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.83M | +31.0% |
| FY2024 | 2024-12-31 | 3.69M | -7.5% |
| FY2023 | 2023-12-31 | 3.99M | -15.2% |
| FY2022 | 2022-12-31 | 4.7M | +9.7% |
| FY2021 | 2021-12-31 | 4.28M | — |
Deferred Revenue vs competitors
How ZYBT compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +31.0% is the 2nd highest of 3, against a peer median of +33.2%.
- Deferred revenue amounts to 1.1% of total assets for ZYBT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $20.31M USD | +0.4% | +30.8% | 21.7% | |
| Dec 2025 | CN¥4.83M CNY | +31.0% | +0.9% | 1.1% | |
| Mar 2026 | $714K USD | +66.0% | — | 1.1% | |
| Mar 2026 | $144K USD | — | -41.6% | 0.2% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | CA$0 CAD | — | — | 0.0% | |
EXOZeXoZymes, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding ZYBT) | — | +33.2% | -5.4% | 0.0% | |
Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.28M | 9.75M | 15.07M | 18.6M | 50.33M |
| Short-term Investments | 0 | 0 | 1.22M | 1.43M | 1.56M |
| Net Receivables | 102.19M | 134.25M | 99.42M | 88.52M | 18.49M |
| Inventory | 43.62M | 55.42M | 58.3M | 58.22M | 39.17M |
| Other Current Assets | 11.14M | 12.46M | 24.03M | 2K | 6.78M |
| Total Current Assets | 164.94M | 214.31M | 205.59M | 177.57M | 137.42M |
| Property, Plant & Equipment (Net) | 255.12M | 283.67M | 271.5M | 255.16M | 237.28M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 12.05M | 19.46M | 16.3M | 22.78M | 54.76M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 10.99M | 0 |
| Other Non-current Assets | 13.17M | 2.23M | 6.5M | 26.75M | 7.01M |
| Total Non-current Assets | 280.34M | 305.37M | 294.3M | 315.68M | 299.05M |
| Total Assets | 445.28M | 519.67M | 499.89M | 493.25M | 436.47M |
| Account Payables | 77.57M | 79.28M | 45.66M | 42.96M | 44.01M |
| Short-term Debt | 30M | 54.89M | 79.86M | 81.63M | 65.8M |
| Tax Payables | 6.81M | 10M | 2.3M | 2.07M | 2.35M |
| Deferred Revenue | 4.28M | 4.7M | 3.99M | 3.69M | 4.83M |
| Other Current Liabilities | 0 | 0 | 0 | 3.28M | 397K |
| Total Current Liabilities | 125.63M | 152.23M | 150.23M | 135.91M | 120.48M |
| Long-term Debt | 0 | 9.99M | 9.99M | 4.8M | 8.85M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 104K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 816K | 590K | 393K | 0 | 0 |
| Total Non-current Liabilities | 816K | 10.58M | 10.38M | 4.8M | 9.28M |
| Total Liabilities | 126.44M | 162.81M | 160.62M | 140.71M | 129.76M |
| Common Stock | 8K | 8K | 8K | 8K | 8K |
| Retained Earnings | 42.33M | 65.77M | 38.38M | 48.15M | (21.63M) |
| Accumulated OCI | 21.99M | 27.57M | 31.31M | 32.65M | 30.72M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 51.36M | 60.37M | 66.42M | 68.58M | 56.87M |
| Total Equity | 318.84M | 356.87M | 339.27M | 352.54M | 306.72M |
| Total Debt | 30M | 64.88M | 89.85M | 86.43M | 75.08M |
| Net Debt | 23.72M | 55.13M | 74.78M | 67.83M | 24.75M |
Zhengye Biotechnology Holding Limited
NASDAQ:ZYBT
Intrinsic Alpha fair value
Locked
Current Price
$1.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.